FDA discloses third Form 483 to Aurobindo during 2019
Aurobindo has received another Form 483 from the US FDA, after the agency found its response to complaints were ‘not always sound’ for products destined for the US market.
Top Headlines
Global Industry News
-
In the push for innovation, regulators are ahead of the curve as pharma and CROs lag behind
from Outsourcing-Pharma.com
-
Medidata acquired by French software firm Dassault Systèmes for $5.8bn
from Outsourcing-Pharma.com
-
Janssen and Genmab hope for repeat success with next-gen agreement
from BioPharma-Reporter.com
-
Bluebird chooses partner for manufacture of its first approved product
from BioPharma-Reporter.com
Hot Topics
-
Cambrex completes $11m labs and logistics center expansion
Globalisation
-
Athenex suspends Chinese API production after safety concerns
Globalisation
-
Antibiotics biotech hits the wall in difficult times for market
Lifecycle Management
-
Otsuka enters the API business after Astellas asset acquisition
Mergers and Acquisitions
